Delivery details +
Order by fax
Zambia Pharmaceuticals and Healthcare Report Q4
- PDF: Immediate delivery
Zambia Pharmaceuticals and Healthcare Report Q4
2012
- Product Code:BMI08600
- Publication Date:July 2012
- Publisher:Business Monitor
- Product Type: Report
- Pages:43
- ISBN:2049-0097
Zambia Pharmaceuticals and Healthcare Report Q4 2012
BMI View: Zambia's healthcare industry has been boosted this quarter with the news of revived investment via international aid agencies and donations. The Swedish government decided to resume funding; USAID and Merck announced plans to channel capital into training healthcare professionals; and Indian bank EXIM opened a credit line for the construction of rural health posts. Such investment, combined with the government's commitment to increase healthcare and pharmaceuticals spending, is good news for the sector, but risks remain. These include concerns over the quality and security of imported drugs, a need to upgrade national drug control laboratories and allegations of corruption. Headline Expenditure Projections
- Pharmaceuticals: ZMK951bn (US$196mn) in 2011 to ZMK1,096bn (US$207mn) in 2012;
- Healthcare: ZMK5,347bn (US$1.10bn) in 2011 to ZMK6,301bn (US$1.19bn) in 2012; +17.9% in local currency terms and +8.2% in US dollar terms. Forecast lowered slightly from Q312. Risk/Reward Rating: In Q412, Zambia remained steady at 21st best market in the MEA region in BMI's proprietary Risk/Reward Ratings (RRR) matrix with a score of 39.6. Key Trends & Developments
- International investment and funding, from banks, aid agencies and private industry, has seen a revival this quarter with the news that USAID and Merck will donate US$8mn to Zambia's Management and Leadership Academy. Sweden's government announced plans to resume funding with an US$6.25mn health investment programme and India's EXIM Bank provided the government with a US$50mn credit line for the construction of 650 rural health clinics.
- Zambia's Pharmaceutical Regulatory Authority called for an upgrade of the national drug quality control laboratory in July 2012 to analyse imported drugs.
- Germany's Conventium International Ltd announced plans to invest in Zambia's textile and drug sectors in July 2012, including investment in new hospitals and healthcare facilities in collaboration with private investors. BMI Economic View: Restrictions on the use of foreign currency in Zambia, introduced in May 2012, has pushed up demand for the Zambian kwacha. While this has had a positive impact on strengthening its value, and the Bank of Zambia has insisted that the country would keep a 'liberal' foreign exchange rate policy, the move will nevertheless generate some concerns in the private sector, particularly in mining. The economic health of Zambia is also closely linked to copper prices, which dropped in July 2012. Zambia Pharmaceuticals & Healthcare Report Q4 2012
- BMI Industry View
- Industry Business Environment Overview
- Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q412
- Pharmaceutical Risk/Reward Ratings
- Rewards
- Risks
- Market Summary
- Government Healthcare Reform
- Regulatory Regime
- Pharmacovigilance (PV)
- Industry Forecast Scenario
- Pharmaceutical Market Forecast
- Table: Pharmaceutical Sales Indicators 2008-2016
- Healthcare Market Forecast
- Table: Healthcare Expenditure Indicators 2008-2016
- Table: Healthcare Governmental Indicators 2008-2016
- Table: Healthcare Private Indicators 2008-2016
- Key Growth Factors - Macroeconomic
- Table: Zambia's Population By Age Group, 1990-2020 ('000)
- Table: Zambia's Population By Age Group, 1990-2020 (% of total)
- Table: Zambia's Key Population Ratios, 1990-2020
- Table: Zambia's Rural And Urban Population, 1990-2020
- Glossary
- BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
